Table 1 Baseline demographics and cancer characteristics
Treatment group | |||
|---|---|---|---|
Characteristics | NAC (27) | NACRT (28) | p value |
Age, median (range), years | 66.0 (40–79) | 68.0 (42–78) | p = 0.64* |
Gender (male), n (%) | 17 (63%) | 16 (57%) | p = 0.79 |
Pretreatment serum CEA level, average (range), ml/dl | 4.7 (0.9–646) | 6.2 (1.5–1244) | p = 0.26* |
Tumor size, average (range), cm | 5.0 (2–10) | 4.9 (2–10) | p = 0.91* |
Distance from anal verge (< 5 cm), n (%) | 17 (63%) | 19 (68%) | p = 0.78 |
Tumor differentiation, n (%) | |||
Well, moderate | 26 (96%) | 27 (96%) | p = 1.00 |
Muc | 1 (3.7%) | 1 (3.6%) | |
cT category, n (%) | |||
pT3 | 24 (89%) | 22 (71%) | p = 0.46 |
pT4a | 3 (11%) | 5 (18%) | |
cN category, n (%) | |||
pN1 | 18 (67%) | 17 (61%) | p = 0.78 |
pN2 | 9 (33%) | 11 (39%) | |
Operation approach (lap), n (%) | 23 (85%) | 16 (57%) | p = 0.037 |
Operative method, n (%) | |||
Low anterior resection | 19 (70%) | 8 (29%) | p = 0.003 |
Abdominoperineal excision | 8 (30%) | 20 (71%) | |
LPLN dissection (yes), n (%) | 9 (33%) | 5 (18%) | p = 0.16 |
Postoperative adjuvant chemotherapy (yes), n (%) | 9 (33%) | 12 (43%) | p = 0.58 |